New drug duo targets tough leukemia cases

NCT ID NCT03328273

First seen Sep 30, 2025 · Last updated May 13, 2026 · Updated 21 times

Summary

This early-phase study tests a new combination of two drugs, acalabrutinib and ceralasertib, in people with a high-risk form of chronic lymphocytic leukemia (CLL) that has come back or stopped responding to other treatments. The main goal is to check the safety and how well the drugs work together. Only 12 participants are enrolled, and the study is no longer recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Krakow, 30-510, Poland

  • Research Site

    Lodz, 93-510, Poland

  • Research Site

    Birmingham, B9 5SS, United Kingdom

  • Research Site

    Bournemouth, BH7 7DW, United Kingdom

  • Research Site

    Cardiff, CF14 4XW, United Kingdom

  • Research Site

    Leeds, LS9 7TF, United Kingdom

  • Research Site

    London, NW1 2PG, United Kingdom

  • Research Site

    London, SE5 9RS, United Kingdom

  • Research Site

    Nottingham, NG5 1PB, United Kingdom

  • Research Site

    Oxford, OX3 7LJ, United Kingdom

  • Research Site

    Southampton, SO16 6YD, United Kingdom

Conditions

Explore the condition pages connected to this study.